Table 1.
Anthropometric, Endocrine, and Metabolic Characteristics of Patients Before and After the Start of Treatment With Metreleptin
| Parameter/Time of Treatment | Patient A |
Patient B |
||||||
|---|---|---|---|---|---|---|---|---|
| Day 0 | Day 4 | Day 9 | Week 8 | Day 0 | Day 4 | Day 9 | Week 8 | |
| Age, mo | 117 | 117 | 117 | 119 | 76 | 76 | 76 | 78 |
| Weight, kg | 77.9 | 78.1 | 76.7 | 71.7 | 50.4 | 51.3 | 50.6 | 46.6 |
| BMI, kg/m2 | 39.6 | 39.7 | 39.0 | 35.8 | 35.2 | 35.8 | 35.3 | 31.7 |
| BMI z-score | 3.5 | 3.5 | 3.5 | 3.3 | 4.1 | 4.1 | 4.1 | 3.8 |
| Leptin, ng/mL | 59.7 | 56.2 | 46.9 | 64 | 74.6 | nd | 56.8 | 20.4 |
| Insulin, mU/L | 32.5 | 30.6 | 51.1 | 22.7 | 19.8 | 13.8 | 8.8 | 10.8 |
| C-peptide, ng/mL | 3.8 | 3.6 | 4.6 | 3 | 3 | 2.8 | 1.8 | 2.2 |
| Triglycerides, mmol/L | 1.4 | 1.5 | 1.6 | 1.5 | 0.8 | 1.2 | 0.4 | 0.9 |
| ALT, U/L | 20 | 18 | 21 | 35 | 16 | 32 | 41 | 37 |
| AST, U/L | 22 | 25 | 27 | 35 | 25 | 36 | 53 | 43 |
| GGT, U/L | 15 | 14 | nd | 11 | 17 | 19 | nd | 30 |
| Cortisol, μg/dL | 4.8 | 5.8 | 5.8 | 16.3 | 8.8 | 8.5 | 9.5 | 5.1 |
| IGF-1, ng/mL | 134 | 129 | 133 | 153 | 41 | 54 | 54 | 70 |
| IGFBP-3, ng/mL | 3360 | 3470 | 3950 | 3590 | 1830 | 2450 | 2400 | 2560 |
| LH, U/L | <0.1 | <0.1 | nd | <0.1 | <0.1 | <0.1 | nd | <0.1 |
| FSH, U/L | 0.3 | 0.3 | nd | 1.05 | 0.6 | nd | nd | 1.8 |
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; GGT, γ-glutamyl transpeptidase; IGFBP-3, IGF binding protein 3; nd, not determined.